Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update
Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American Society of Hematology Annual Meeting Received ...
Future Market Insights17h
Global Anti-Fungal Therapy Market Poised for Growth, Projected to Reach USD 22.8 Billion by 2033 expand at a CAGR of 4.7%
Anti-Fungal Therapy Market. The global anti-fungal therapy market is set to experience significant growth, with a projected ...
Benzinga.com13h
Gilead Sciences (NASDAQ:GILD) Stock Quotes, Forecast and News Summary
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. Galapagos NV plans to split into two entities ...
stocknews4h
Is Exelixis a Biotech Stock Worth Adding to Your Portfolio?
Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...
pharmaphorum21h
Baillie Gifford, Moderna’s largest shareholder, shares investment strategies
It currently hosts 40 companies in its portfolio. A patient's healthcare experience currently centres on obtaining treatment only once they get sick. Ultimately, Torrance says healthcare will ...